Abstract: Roxadustat (FG-4592) is a first-in-class, orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). While initially approved for the treatment of anemia in chronic kidney disease (CKD), its therapeutic potential is actively being explored in myelodysplastic syndromes (MDS)-associated anemia and chemotherapy-induced anemia (CIA). By mimicking hypoxia, Roxadustat stabilizes HIF-α subunits, thereby stimulating endogenous erythropoietin (EPO) production and optimizing iron metabolism. This review comprehensively examines the pharmacological activity, molecular mechanisms, and structure-activity relationships of Roxadustat. Furthermore, it critically addresses current clinical limitations, particularly the theoretical risks of tumor progression and off-target enzymatic inhibition, and outlines future perspectives for its safe integration into hematological and oncological care.
1. Introduction
Anemia is a pervasive and debilitating complication in patients with chronic kidney disease (CKD), myelodysplastic syndromes (MDS), and those undergoing myelosuppressive chemotherapy. Historically, the management of anemia in these populations has relied heavily on red blood cell (RBC) transfusions and erythropoiesis-stimulating agents (ESAs) [2][6]. However, ESAs are associated with primary resistance in a significant subset of MDS patients and carry risks of cardiovascular events, venous thromboembolism, and potential tumor progression in cancer patients [2][6]. Roxadustat (FG-4592) has emerged as a novel, orally bioavailable alternative that stimulates erythropoiesis by stabilizing hypoxia-inducible factors (HIFs) [1][5]. Following its clinical success and regulatory approval for CKD-related anemia, research directions have expanded to evaluate its efficacy and safety in treating MDS-associated anemia and chemotherapy-induced anemia (CIA), offering a potential paradigm shift in how these conditions are managed [4][6].
2. Pharmacological Activity
Roxadustat exhibits potent erythropoiesis-stimulating activity by increasing endogenous EPO levels within or near the normal physiologic range, which efficiently stimulates hematopoietic stem cells without the massive EPO spikes seen with exogenous ESAs [1][8]. In the context of MDS, where anemia is a major therapeutic challenge due to ineffective erythropoiesis and high rates of ESA resistance, Roxadustat is currently under investigation in phase 3 randomized, double-blind, placebo-controlled trials (e.g., NCT03263091, NCT03303066) aimed at achieving transfusion independence and sustained hemoglobin increases in lower-risk MDS patients with a low RBC transfusion burden [2][4][5].
For chemotherapy-induced anemia (CIA), recent phase III clinical data demonstrate that oral Roxadustat is non-inferior to ESAs in correcting hemoglobin levels in patients with non-myeloid malignancies receiving multi-cycle chemotherapy [6]. Beyond stimulating EPO, Roxadustat exerts profound effects on iron metabolism. It significantly reduces serum hepcidin levels, increases total iron-binding capacity (TIBC), and upregulates iron transporters such as divalent metal transporter 1 (DMT1), duodenal cytochrome B (DcytB), and ferroportin. This coordinated response enhances intestinal iron absorption and mobilization from macrophages, effectively overcoming functional iron deficiency [4][5][17].
3. Molecular Mechanism of Action
The molecular mechanism of Roxadustat centers on the oxygen-sensing pathway regulated by HIFs. Under normoxic conditions, prolyl hydroxylase domain (PHD) enzymes (specifically PHD1, PHD2, and PHD3) hydroxylate specific proline residues on the HIF-α subunit [3][6]. This hydroxylation allows the von Hippel-Lindau (VHL) protein to recognize and ubiquitinate HIF-α, marking it for rapid proteasomal degradation [6].
Roxadustat acts as a reversible inhibitor of these PHD enzymes. By inhibiting PHD activity, Roxadustat prevents the oxygen-dependent degradation of HIF-1α and HIF-2α, allowing them to accumulate, translocate to the nucleus, and dimerize with the constitutively expressed HIF-1β subunit [3][10]. The active HIF heterodimer then binds to hypoxia response elements (HREs) in the promoter regions of target genes. This drives the transcription of the EPO gene and genes essential for iron transport and utilization, effectively tricking the body into mounting an orchestrated erythropoietic response as if it were experiencing hypoxia [5][6].
4. Structure-Activity Relationship (SAR)
Roxadustat is a small molecule with the chemical formula C19H16N2O5 and a molecular weight of 352.34 g/mol [1]. Structurally, it is designed to mimic 2-oxoglutarate (2-OG), which is a necessary co-substrate for the catalytic activity of PHD enzymes [10]. By acting as a 2-OG analogue, Roxadustat competitively binds to the active site of the PHD enzymes, effectively blocking their ability to hydroxylate HIF-α [10].
However, because PHDs belong to a larger superfamily of 2-OG-dependent dioxygenases (2-OGDDs), the structural similarity of Roxadustat to 2-OG means it has the potential to interact with other enzymes within this family. For instance, Roxadustat and inhibitors of collagen prolyl 4-hydroxylase (CP4H)—another non-heme iron(II)-containing 2-OGDD—share structural analogies. This structural overlap forms the basis for some of its off-target pharmacological effects, as the drug can inadvertently inhibit other enzymes that rely on the 2-OG co-substrate [10].
5. Current Limitations
The application of Roxadustat in oncology and hematology is accompanied by significant clinical concerns. The primary limitation in treating CIA is the potential oncogenic risk associated with HIF-1α stabilization. HIF-1α activation is known to promote tumor progression through metabolic reprogramming (upregulating GLUT1, HK2, and LDHA for glucose metabolism), stimulating angiogenesis via VEGF, inducing epithelial-mesenchymal transition (EMT), and facilitating immune evasion by upregulating PD-L1 [6]. Although short-term studies have not shown a definitive causal link to new malignancies, tumor progression events have been reported as serious adverse events in CIA trials, creating a clinical dilemma [6].
Furthermore, off-target inhibition of other 2-OGDDs, such as CP4H, can impair the hydroxylation of complement C1q and mannose-binding lectin (MBL), potentially compromising innate immune responses and inflammatory mechanisms [10]. Additionally, there are unresolved concerns regarding thromboembolic events and the potential induction of pulmonary hypertension, which may be linked to HIF-2α stabilization promoting vascular remodeling [7][8].
6. Future Perspectives
To safely integrate Roxadustat into the treatment paradigms for MDS and CIA, future research must prioritize long-term longitudinal surveillance to definitively assess the benefit-risk profile concerning tumor progression and metastasis [6]. Because the hemoglobin response to Roxadustat is long-lasting and potentially irreversible at the erythrocyte level, investigating intermittent or periodic dosing regimens could be a viable strategy to maximize therapeutic efficacy while minimizing continuous HIF activation and its associated oncogenic risks [1].
Additionally, identifying prognostic biomarkers will be crucial to define the specific subsets of MDS and cancer patients who will benefit most from HIF-PHI therapy without experiencing adverse tumor-related or thromboembolic outcomes [2][6]. As clinical experience grows, the pleiotropic effects of Roxadustat on iron metabolism and inflammation may also open new avenues for its use, provided its safety profile in high-risk populations is rigorously validated.
